Technologies

The virtual dynamic docking, carried out in the MOLBD3 lab of the Institute of Biophysics, allows the identification of new drugs through the structural information deriving from the study of target proteins, responsible for some human pathologies. In particular, we screen drugs or small molecules (commercial/own libraries) against known protein sites, surface cavities, surfaces of protein-protein interactions (fixed/rigid hotspots) or structural transition states (dynamic hotspots).

We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.

Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules: